Difference between revisions of "Template:Antiarrhythmic agents"

From blackwiki
Jump to navigation Jump to search
blackwiki>Arcadian
(cat)
m (67 revisions imported)
 
(18 intermediate revisions by 13 users not shown)
Line 2: Line 2:
 
| name  = Antiarrhythmic agents
 
| name  = Antiarrhythmic agents
 
| title = [[Antiarrhythmic agent]]s ([[ATC code C01#C01B|C01B]])
 
| title = [[Antiarrhythmic agent]]s ([[ATC code C01#C01B|C01B]])
| groupstyle = background:MistyRose;
+
| state = {{{state|autocollapse}}}
 +
|listclass = hlist
  
 
|group1  = [[Channel blocker]]s
 
|group1  = [[Channel blocker]]s
|list1  = {{Navbox subgroup
+
|list1  = {{Navbox|subgroup
| groupstyle = background:MistyRose;
 
  
| group1 = [[Antiarrhythmic_agent#Class_I_agents|class I]]<BR>([[sodium channel blocker|Na<sup>+</sup> channel blockers]])
+
| group1 = [[Antiarrhythmic agent#Class I agents|class I]]<BR>([[sodium channel blocker|Na<sup>+</sup> channel blockers]])
| list1  = {{Navbox subgroup
+
| list1  = {{Navbox|subgroup
  | groupstyle = background:MistyRose;
 
  
   | group1 = class Ia ([[Cardiac_action_potential#Phase_0|Phase 0]]→ and [[Cardiac_action_potential#Phase_3|Phase 3]]→)
+
   | group1 = class Ia ([[Cardiac action potential#Phase 0|Phase 0]]→ and [[Cardiac action potential#Phase 3|Phase 3]]→)
   | list1  = [[Procainamide]]&nbsp;#&nbsp;•  [[Quinidine]]&nbsp;#&nbsp;•  [[Ajmaline]]&nbsp;•  [[Disopyramide]]&nbsp;•  [[Prajmaline]]&nbsp;•  [[Lorajmine]]&nbsp;•  [[Sparteine]]
+
   | list1  =
 +
* [[Ajmaline]]
 +
* [[Disopyramide]]
 +
* [[Dihydroquinidine|Hydroquinidine]]
 +
* [[Lorajmine]]
 +
* [[Prajmaline]]
 +
* [[Procainamide]]<sup>#</sup>
 +
* [[Quinidine]]<sup>#</sup>
 +
* [[Sparteine]]
  
   | group2 = class Ib ([[Cardiac_action_potential#Phase_3|Phase 3]]←)
+
   | group2 = class Ib ([[Cardiac action potential#Phase 3|Phase 3]]←)
   | list2  = ''[[Intravenous therapy|IV]]'' ([[Lidocaine]]&nbsp;#)&nbsp;•  ''[[enteral]]'' ([[Mexiletine]], [[Tocainide]], [[Aprindine]])
+
   | list2  =
 +
* ''[[Intravenous therapy|IV]]''
 +
** [[Lidocaine]]<sup>#</sup>
 +
* ''[[enteral]]''
 +
** [[Aprindine]]
 +
** [[Mexiletine]]
 +
** [[Tocainide]]
  
   | group3 = class Ic ([[Cardiac_action_potential#Phase_0|Phase 0]]→)
+
   | group3 = class Ic ([[Cardiac action potential#Phase 0|Phase 0]]→)
   | list3  = [[Encainide]]&nbsp;•  [[Flecainide]]&nbsp;•  [[Lorcainide]]&nbsp;•  [[Moricizine]]‡&nbsp;•  [[Propafenone]]  
+
   | list3  =
 +
* [[Encainide]]<sup>‡</sup>
 +
* [[Ethacizine]]
 +
* [[Flecainide]]
 +
* [[Indecainide]]<sup>‡</sup>
 +
* [[Lorcainide]]
 +
* [[Moracizine]]<sup></sup>
 +
* [[Propafenone]]  
  
 
   }}
 
   }}
  
| group3 = [[Antiarrhythmic_agent#Class_III_agents|class III]]<BR>([[Cardiac_action_potential#Phase_3|Phase 3]]→, [[potassium channel blocker|K<sup>+</sup> channel blockers]])
+
| group3 = [[Antiarrhythmic agent#Class III agents|class III]]<BR>([[Cardiac action potential#Phase 3|Phase 3]]→, [[potassium channel blocker|K<sup>+</sup> channel blockers]])
| list3  = [[Amiodarone]]&nbsp;•  [[Dronedarone]]&nbsp;•  [[Bretylium]]&nbsp;•  [[Bunaftine]]&nbsp;•  [[Dofetilide]]&nbsp;•  [[Ibutilide]]&nbsp;•  [[Nifekalant]]&nbsp;•  [[Sotalol]]&nbsp;•  [[Tedisamil]]&nbsp;•  [[Vernakalant]]&nbsp;•  [[E-4031]]
+
| list3  =
 
+
* [[Amiodarone]]
| group4 = [[Antiarrhythmic_agent#Class_IV_agents|class IV]]<br/>([[Cardiac_action_potential#Phase_4|Phase 4]]→, [[calcium channel blocker|Ca<sup>2+</sup> channel blockers]])
+
* [[Bretylium]]
| list4  = [[Verapamil]]&nbsp;#&nbsp;•  [[Diltiazem]]
+
* [[Bunaftine]]
 +
* [[Celivarone]]<sup>†</sup>
 +
* [[Dofetilide]]
 +
* [[Dronedarone]]
 +
* [[E-4031]]<sup>†</sup>
 +
* [[Ibutilide]]
 +
* [[Nifekalant]]
 +
* [[Sotalol]]
 +
* [[Tedisamil]]
 +
* [[Vernakalant]]
  
 +
| group4 = [[Antiarrhythmic agent#Class IV agents|class IV]]<br/>([[Cardiac action potential#Phase 4|Phase 4]]→, [[calcium channel blocker|Ca<sup>2+</sup> channel blockers]])
 +
| list4  =
 +
* [[Diltiazem]]
 +
* [[Verapamil]]<sup>#</sup>
  
 
}}
 
}}
  
 
|group2  = [[Receptor (biochemistry)|Receptor]] [[agonist]]s<BR>and [[Receptor antagonist|antagonist]]s
 
|group2  = [[Receptor (biochemistry)|Receptor]] [[agonist]]s<BR>and [[Receptor antagonist|antagonist]]s
|list2  = {{Navbox subgroup
+
|list2  = {{Navbox|subgroup
| groupstyle = background:MistyRose;
 
  
| group2 = [[Antiarrhythmic_agent#Class_II_agents|class II]]<br/>([[Cardiac_action_potential#Phase_4|Phase 4]]→, [[beta blocker|β blocker]]s)
+
| group2 = [[Antiarrhythmic agent#Class II agents|class II]]<br/>([[Cardiac action potential#Phase 4|Phase 4]]→, [[beta blocker|β blocker]]s)
| list2  = [[Propranolol]]&nbsp;•  [[Nadolol]]&nbsp;•  [[Pindolol]]&nbsp;•  ''cardioselective'' ([[Atenolol]], [[Metoprolol]], [[Acebutolol]], [[Esmolol]])
+
| list2  =
 +
* [[Nadolol]]
 +
* [[Pindolol]]
 +
* [[Propranolol]]
 +
* ''cardioselective''
 +
** [[Acebutolol]]
 +
** [[Atenolol]]
 +
** [[Esmolol]]
 +
** [[Metoprolol]]
  
| group5 = [[adenosine A1 receptor|A1 agonist]]
+
| group5 = [[adenosine A1 receptor|A<sub>1</sub> agonist]]
| list5  = [[Adenosine]]
+
| list5  =
 +
* [[Adenosine]]
 +
* [[Benzodiazepine]]s
 +
* [[Barbiturate]]s
  
| group6 = [[Muscarinic acetylcholine receptor M2|M2]]
+
| group6 = [[Muscarinic acetylcholine receptor M2|M<sub>2</sub>]]
| list6  = [[muscarinic antagonist]]: [[Atropine]]&nbsp;•  [[Quinidine]]&nbsp;•  [[Disopyramide]]<BR>[[muscarinic agonist]]: [[Digoxin]]
+
| list6  =
 
+
* [[muscarinic antagonist]]: [[Atropine]]
| group7 = [[Adrenergic_receptor#.CE.B1_receptors|α receptors]]
+
* [[Disopyramide]]
| list7  = [[Quinidine]]&nbsp;•  [[Verapamil]]&nbsp;•  [[Amiodarone]]&nbsp;•  [[Bretylium]]
+
* [[Quinidine]]<BR>[[muscarinic agonist]]: [[Digoxin]]
  
 +
| group7 = [[Adrenergic receptor#.CE.B1 receptors|α receptors]]
 +
| list7  =
 +
* [[Amiodarone]]
 +
* [[Bretylium]]
 +
* [[Quinidine]]
 +
* [[Verapamil]]
  
 
}}
 
}}
 
  
 
| group8 = [[Ion transporter]]s
 
| group8 = [[Ion transporter]]s
| list8  = {{Navbox subgroup
+
| list8  = {{Navbox|subgroup
  | groupstyle = background:MistyRose;
 
 
 
| group1 = [[Na%E2%81%BA/K%E2%81%BA-ATPase|Na<sup>+</sup> / K<sup>+</sup>-ATPase]]
 
| list1  = [[Digoxin]]
 
  
 +
| group1 = [[Na+/K+-ATPase|Na<sup>+</sup>/ K<sup>+</sup>-ATPase]]
 +
| list1  =
 +
* [[Digitoxin]]
 +
* [[Digoxin]]
 +
* [[Ouabain]]
  
 
}}
 
}}
 
  
 
| group9 =  
 
| group9 =  
 
| list9  = {{PharmNavFootnote}}
 
| list9  = {{PharmNavFootnote}}
 
| belowstyle = background: transparent; padding: 0px;
 
| below = {{Heart navs}}
 
  
 
}}<noinclude>
 
}}<noinclude>
[[Category:Drugs acting on the cardiovascular system]]
+
{{collapsible option}}
[[Category:Drug_templates by ATC|{{PAGENAME}}]]
+
[[Category:Antiarrhythmic agents]]
[[hu:Sablon:AntiarritmiásSzerek]]
+
[[Category:Drug templates by ATC]]
 
</noinclude>
 
</noinclude>

Latest revision as of 14:15, 22 October 2020

Initial visibility: currently defaults to autocollapse

To set this template's initial visibility, the |state= parameter may be used:

  • |state=collapsed: {{Antiarrhythmic agents|state=collapsed}} to show the template collapsed, i.e., hidden apart from its title bar
  • |state=expanded: {{Antiarrhythmic agents|state=expanded}} to show the template expanded, i.e., fully visible
  • |state=autocollapse: {{Antiarrhythmic agents|state=autocollapse}}
    • shows the template collapsed to the title bar if there is a {{navbar}}, a {{sidebar}}, or some other table on the page with the collapsible attribute
    • shows the template in its expanded state if there are no other collapsible items on the page

If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.